CC BY-NC-ND 4.0 · South Asian J Cancer 2023; 12(01): 081-086
DOI: 10.1055/s-0042-1755582
Original Article
Ovarian Cancer

Evaluation of Outcomes of Mucinous Ovarian Cancer Treated at a Tertiary Care Cancer Hospital in Pakistan

1   Department of Medical Oncology, Shaukat Khanum Cancer Hospital, Lahore, Pakistan
Musa Azhar
1   Department of Medical Oncology, Shaukat Khanum Cancer Hospital, Lahore, Pakistan
Abdul Wahab
1   Department of Medical Oncology, Shaukat Khanum Cancer Hospital, Lahore, Pakistan
Tahira Yasmeen
1   Department of Medical Oncology, Shaukat Khanum Cancer Hospital, Lahore, Pakistan
Neelam Siddiqui
1   Department of Medical Oncology, Shaukat Khanum Cancer Hospital, Lahore, Pakistan
› Author Affiliations
Funding None.


Zoom Image
Syed Abdul Mannan Hamdani

Objective To evaluate the clinicopathological features and survival outcomes of mucinous ovarian cancer (MOC) patients in an Asian population.

Study Design Descriptive observational study.

Place and Duration of Study Shaukat Khanum Memorial Cancer Hospital, Lahore, Pakistan, from January 2001 to December 2016.

Methods Data of MOC were evaluated for demographics, tumor stage, clinical characteristics, tumor markers, treatment modalities, and outcomes from electronic Hospital Information System.

Results Nine-hundred patients with primary ovarian cancer were reviewed, out of which 94 patients (10.4%) had MOC. The median age was 36 ± 12.4 years. The most common presentation was abdominal distension 51 (54.3%), while the rest presented with abdominal pain and irregular menstruation. Using FIGO (The International Federation of Gynecology and Obstetrics) staging, 72 (76.6%) had stage I, 3 (3.2%) stage II, stage III in 12 (12.8%), and 7 (7.4%) had stage IV disease. The majority of patients 75 (79.8%) had early-stage (stage I/II), while 19 (20.2%) presented with advanced-stage (III & IV). The median follow-up duration was 52 months (range 1–199 months). Among patients with early-stage (I&II), 3- and 5-year progression-free survival (PFS) was 95%, while for advanced stage (III&IV), PFS was 16% and 8%, respectively. The overall survival (OS) in early-stage I&II was 97%, while for advanced stages III & IV, the OS was 26%.

Conclusion MOC is a challenging and rare subtype of ovarian cancer requiring special attention and recognition. Most patients treated at our center presented with early stages and had excellent outcomes, while advanced-stage disease had dismal results.

Publication History

Article published online:
22 August 2022

© 2022. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

  • References

  • 1 Morice P, Gouy S, Leary A. Mucinous ovarian carcinoma. N Engl J Med 2019; 380 (13) 1256-1266
  • 2 Hess V, A'Hern R, Nasiri N. et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 2004; 22 (06) 1040-1044
  • 3 Gorringe KL, Cheasley D, Wakefield MJ. et al. Therapeutic options for mucinous ovarian carcinoma. Gynecol Oncol 2020; 156 (03) 552-560
  • 4 Xu W, Rush J, Rickett K, Coward JI. Mucinous ovarian cancer: a therapeutic review. Crit Rev Oncol Hematol 2016; 102: 26-36
  • 5 Brown J, Frumovitz M. Mucinous tumors of the ovary: current thoughts on diagnosis and management. Curr Oncol Rep 2014; 16 (06) 389
  • 6 Ricci F, Affatato R, Carrassa L, Damia G. Recent insights into mucinous ovarian carcinoma. Int J Mol Sci 2018; 19 (06) 1569
  • 7 Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 2003; 27 (07) 985-993
  • 8 Zaino RJ, Brady MF, Lele SM, Michael H, Greer B, Bookman MA. Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study. Cancer 2011; 117 (03) 554-562
  • 9 Bamias A, Psaltopoulou T, Sotiropoulou M. et al. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer 2010; 116 (06) 1462-1468
  • 10 Peres LC, Cushing-Haugen KL, Köbel M. et al. Invasive epithelial ovarian cancer survival by histotype and disease stage. J Natl Cancer Inst 2019; 111 (01) 60-68
  • 11 Schiavone MB, Herzog TJ, Lewin SN. et al. Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol 2011; 205 (05) 480.e1-480.e8
  • 12 Pectasides D, Fountzilas G, Aravantinos G. et al. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2005; 97 (02) 436-441
  • 13 Simons M, Ezendam N, Bulten J, Nagtegaal I, Massuger L. Survival of patients with mucinous ovarian carcinoma and ovarian metastases: a population-based cancer registry study. Int J Gynecol Cancer 2015; 25 (07) 1208-1215
  • 14 Ahmad Z, Idrees R, Fatima S. et al. Commonest cancers in Pakistan-findings and histopathological perspective from a premier surgical pathology center in Pakistan. Asian Pac J Cancer Prev 2016; 17 (03) 1061-1075
  • 15 Sarwar CM, Siddiqui N, Khokhar RA, Badar F. Epithelial ovarian cancer at a cancer hospital in a developing country. Asian Pac J Cancer Prev 2006; 7 (04) 595-598
  • 16 Shimada M, Kigawa J, Ohishi Y. et al. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol 2009; 113 (03) 331-334
  • 17 Mehmood S, Khan MQ. Mucinous adenocarcinoma ovary: diagnostic dilemma and the usefulness of colonoscopy. J Ayub Med Coll Abbottabad 2015; 27 (02) 280-283
  • 18 Choi JH, Sohn GS, Chay DB, Cho HB, Kim J-H. Preoperative serum levels of cancer antigen 125 and carcinoembryonic antigen ratio can improve differentiation between mucinous ovarian carcinoma and other epithelial ovarian carcinomas. Obstet Gynecol Sci 2018; 61 (03) 344-351
  • 19 Lee JY, Jo YR, Kim TH. et al. Safety of fertility-sparing surgery in primary mucinous carcinoma of the ovary. Cancer Res Treat 2015; 47 (02) 290-297
  • 20 Kajiyama H, Shibata K, Suzuki S. et al. Fertility-sparing surgery in young women with invasive epithelial ovarian cancer. Eur J Surg Oncol 2010; 36 (04) 404-408 (EJSO)
  • 21 Kajiyama H, Shibata K, Mizuno M. et al. Fertility-sparing surgery in young women with mucinous adenocarcinoma of the ovary. Gynecol Oncol 2011; 122 (02) 334-338
  • 22 Perren TJ. Mucinous epithelial ovarian carcinoma. Ann Oncol 2016; 27 (Suppl. 01) i53-i57
  • 23 Nasioudis D, Albright BB, Ko EM. et al. Advanced stage primary mucinous ovarian carcinoma. Where do we stand?. Arch Gynecol Obstet 2020; 301 (04) 1047-1054
  • 24 Crane EK, Brown J. Early stage mucinous ovarian cancer: a review. Gynecol Oncol 2018; 149 (03) 598-604
  • 25 Mueller JJ, Lajer H, Mosgaard BJ. et al. International study of primary mucinous ovarian carcinomas managed at tertiary medical centers. Int J Gynecol Cancer 2018; 28 (05) 915-924
  • 26 Mackay HJ, Brady MF, Oza AM. et al; Gynecologic Cancer InterGroup. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 2010; 20 (06) 945-952
  • 27 Das G, Sridevi V, Natarajan M. A tertiary cancer center experience of 52 cases of primary ovarian mucinous adenocarcinomas. South Asian J Cancer 2020; 9 (02) 90-92